Abstract Search

ey0017.5-2 | Advances in Clinical Practice | ESPEYB17

5.2. Osteogenesis Imperfecta: Skeletal outcomes after bisphosphonate discontinuation at final height

ME Robinson , P Trejo , T Palomo , FH Glorieux , F Rauch

To read the full abstract: J Bone Miner Res. 2019 Dec;34(12):21982204.In brief: In Osteogenesis imperfecta (OI), intravenous (IV) cyclical bisphosphonates are often discontinued after cessation of growth in adolescents. This study showed that, four years after discontinuation of treatment, none of the patients sustained new vertebral compression fractures, and the proportion ...

0 shares

ey0020.10-12 | Dyslipidemia | ESPEYB20

10.12. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients

SE Nissen , AM Lincoff , D Brennan , KK Ray , D Mason , JJP Kastelein , PD Thompson , P Libby , L Cho , J Plutzky , HE Bays , PM Moriarty , V Menon , DE Grobbee , MJ Louie , CF Chen , N Li , L Bloedon , P Robinson , M Horner , WJ Sasiela , J McCluskey , D Davey , P Fajardo-Campos , P Petrovic , J Fedacko , W Zmuda , Y Lukyanov , SJ Nicholls , CLEAR Outcomes Investigators Nicholls

Brief summary: In this double-blind, randomized, placebo-controlled trial, bempedoic acid (Nexletol) reduced the incidence of a composite cardiovascular.Comment: Bempedoic acid is an ATP citrate lyase inhibitor. ATP citrate lyase catalyses the conversion of citrate to acetyl-CoA, the fundamental substrate required for the synthesis of cholesterol and fatty acids. By inhibiting the cholesterol synthesis pathway, bempedoic acid reduces intra-hepatic LDL-C....

1 shares

ESPE Yearbook of Paediatric Endocrinology

5.2. Osteogenesis Imperfecta: Skeletal outcomes after bisphosphonate discontinuation at final height

10.12. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients

BiosciAbstracts